Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
about
Immune Cells in Cancer Therapy and Drug DeliveryNew Strategies for the Treatment of Solid Tumors with CAR-T CellsT cell receptor mimic antibodies for cancer therapyAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectGenetically modified T cells for the treatment of malignant diseaseMolecular mechanisms of T cell co-stimulation and co-inhibitionImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaTherapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Toxicity and management in CAR T-cell therapyAdvances in Cancer Immunotherapy in Solid TumorsGenome-Edited T Cell Therapies.Cancer immunotherapy in clinical practice -- the past, present, and future.EBV-positive diffuse large B-cell lymphoma of the elderlyImproving the safety of cell therapy with the TK-suicide geneRe-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Establishing Tolerance to Commensal Skin Bacteria: Timing Is Everything.The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.Immune-based Therapy Clinical Trials in Hepatocellular CarcinomaDiacylglycerol kinases: regulated controllers of T cell activation, function, and development.IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopeniaDesign and development of therapies using chimeric antigen receptor-expressing T cellsGenetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors.Immunotherapy for opportunistic infections: Current status and future perspectives.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.New development in CAR-T cell therapy.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Current and future directions for Phase II trials in high-grade glioma.Therapies currently in Phase II trials for malignant pleural mesothelioma.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Sequence analysis of T-cell repertoires in health and disease.CAR T cells: driving the road from the laboratory to the clinic.Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections.
P2860
Q26747061-4232E860-7A18-4D19-8A2C-D2D1321A7892Q26748500-C594DF87-51EC-4F63-8DE4-9C0B341AE0B4Q26768271-274982BD-1F2B-4970-91A7-94EE06874B46Q26775720-C4D6BBCA-F514-45CB-9466-8E2FDC52524BQ26826830-19AB497C-53BC-4B80-A555-080C67F8FE48Q26860657-754EF98A-3485-4285-BB55-014CF7173AFFQ26864888-59DDF689-877D-4795-8B8D-2297B9D7C6A5Q26996829-267DFE8F-68C8-4E48-BD16-F59CEE09FB4EQ27021570-EFF268FF-3061-4B4A-A50C-4DDE71DA726EQ27024830-C248B2ED-F236-4C9E-B2BE-840349936803Q27313856-43C61374-578F-448F-B8A0-41B8315278BAQ28075314-E1814CDC-8432-4BEA-B180-8C4964A29021Q28080113-425A3F96-170F-4696-AD78-D2D169AD45D5Q33729598-983BC392-5C05-49EA-A8C6-28D629714803Q34309399-836E5FFE-0C26-447A-801B-E820759742C4Q34343242-4994EB20-E116-4D0C-8B0F-43F621E23BCCQ34477411-81A91DF1-41FF-4812-92D5-125649118CC0Q34520155-AD43278D-A162-4396-B5C7-1AAF801AB0F2Q35399334-84C1E110-9A8B-4597-AFAD-D50D35BD2FAAQ35567765-AECDDAD8-A0A3-4F37-B4B2-86B07BBC8DADQ36204845-42A939E2-C38B-4541-A89E-E21E54650EB2Q36408432-52DE115A-1BC0-45D3-8C0A-B3C9860D9C4BQ36481165-F426BCDD-65A5-4CED-9DAC-2644C0F923D2Q36571270-486F3A37-03E9-4FA3-A5AF-FD353FE3616DQ36820360-039A7370-F169-4036-9F80-12EC9AB8A6E4Q36875832-D63F5717-ED2A-4BF1-8978-B7C60E60C590Q37418289-94DBC3EE-E463-4BDC-8363-DFA4CDC49A25Q37481319-B834D87A-5883-4115-85AA-1E98E522770CQ37509216-B14F35CE-66AB-4965-89D9-DDC2F8E21E70Q37587956-E166B213-AD3E-4FBE-989C-8127B93AEE61Q37592957-15BEF268-EAEA-424A-A246-9B7902CB7607Q37658246-7F7617D7-DD34-474E-82E4-9F4B594E8C4AQ38072056-D64F1EAD-944E-4BFD-ADAD-E8C584AA7030Q38094808-E667DAF7-A6FF-42BA-8A73-D3D9431F4CA6Q38118385-4B181042-1271-44A5-B425-5E72F264CB6EQ38120535-86D60D24-144C-4920-B548-ACF0FDE933F1Q38156565-390902BB-B789-4CC6-92F1-53C7D68E675DQ38170499-01C2C798-DEDF-4DB8-85F8-19657736236AQ38400420-FD09BEC9-0E78-47B1-8AE6-6586346A3642Q38417056-0D9FA8FD-54D3-4981-BE55-18DB958E33E0
P2860
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Chimeric antigen receptors for ...... standing and future directions
@ast
Chimeric antigen receptors for ...... standing and future directions
@en
Chimeric antigen receptors for ...... standing and future directions
@nl
type
label
Chimeric antigen receptors for ...... standing and future directions
@ast
Chimeric antigen receptors for ...... standing and future directions
@en
Chimeric antigen receptors for ...... standing and future directions
@nl
prefLabel
Chimeric antigen receptors for ...... standing and future directions
@ast
Chimeric antigen receptors for ...... standing and future directions
@en
Chimeric antigen receptors for ...... standing and future directions
@nl
P2093
P2860
P356
P1476
Chimeric antigen receptors for ...... standing and future directions
@en
P2093
Hollie J Pegram
Kevin J Curran
Renier J Brentjens
P2860
P304
P356
10.1002/JGM.2604
P577
2012-06-01T00:00:00Z